Xanthine Oxidase Diagnostics – Methods and Relevance

What Is Xanthine Oxidase Diagnostics?

Xanthine oxidase diagnostics encompasses all diagnostic procedures designed to measure and evaluate the activity or presence of the enzyme xanthine oxidase (also known as xanthine dehydrogenase) in the human body. Xanthine oxidase is a key enzyme in purine metabolism and catalyzes the sequential conversion of hypoxanthine to xanthine, and then xanthine to uric acid. Altered enzyme activity can lead to various metabolic diseases and carries significant clinical relevance.

Biological Background of Xanthine Oxidase

Xanthine oxidase is found primarily in the liver and small intestine. The enzyme belongs to the family of molybdoenzymes and requires molybdenum as a cofactor, along with FAD (flavin adenine dinucleotide) and iron-sulfur clusters for its catalytic function. In the context of purine metabolism, xanthine oxidase degrades purines derived from the breakdown of nucleic acids (DNA and RNA). As a byproduct, the enzyme generates reactive oxygen species (ROS), giving it an important role in oxidative stress and inflammatory processes.

Indications for Xanthine Oxidase Diagnostics

Targeted investigation of xanthine oxidase activity is recommended in the following clinical situations:

• Xanthinuria Type I and Type II: Rare inherited metabolic disorders in which xanthine oxidase is completely or nearly completely absent, leading to elevated xanthine and hypoxanthine levels in the urine alongside very low serum uric acid.
• Hyperuricemia and Gout: In patients with elevated uric acid levels and clinical suspicion of gout, increased xanthine oxidase activity may be investigated as the underlying cause of excess uric acid production.
• Molybdenum Cofactor Deficiency: Since xanthine oxidase depends on molybdenum as a cofactor, a deficiency of this trace element can lead to reduced enzyme activity.
• Therapy Monitoring with Allopurinol or Febuxostat: These medications specifically inhibit xanthine oxidase; diagnostics can be used to assess therapeutic effectiveness.
• Ischemia-Reperfusion Injury: In clinical research, xanthine oxidase activity is studied as a biomarker for oxidative stress in tissue damage caused by oxygen deprivation.

Diagnostic Methods

Measurement of Enzyme Activity in Plasma or Tissue

Xanthine oxidase activity can be measured directly in blood plasma or tissue samples (e.g., liver biopsy). Spectrophotometric or fluorimetric assays are used to measure the conversion of xanthine to uric acid under controlled laboratory conditions. Activity is typically expressed in units per milligram of protein (U/mg) or similar units.

Uric Acid and Xanthine Measurement in Blood and Urine

An indirect assessment of xanthine oxidase activity is achieved by measuring serum uric acid as well as xanthine and hypoxanthine in urine. In xanthinuria, serum uric acid levels are typically very low (below 1 mg/dL), while urinary xanthine and hypoxanthine are elevated. These measurements are often performed using High-Performance Liquid Chromatography (HPLC).

Genetic Testing

When hereditary xanthinuria is suspected, molecular genetic testing can be performed. Mutations in the XDH gene (xanthine dehydrogenase gene) in Type I xanthinuria, or in the MOCOS gene (molybdenum cofactor sulfurase) in Type II xanthinuria, can be identified through gene sequencing.

Urinalysis and Kidney Stone Analysis

Since xanthine is poorly soluble, patients with reduced xanthine oxidase activity may develop xanthine kidney stones. Chemical analysis of kidney stones can therefore be an important diagnostic clue pointing toward xanthinuria.

Reference Values and Interpretation

Reference ranges for xanthine oxidase activity in plasma are laboratory-dependent and vary by method. General guidance includes:

• Normal serum uric acid: 3.4 to 7.0 mg/dL (men) and 2.4 to 5.7 mg/dL (women)
• Elevated xanthine oxidase activity: Suggests increased purine catabolism, as seen in gout or tumor lysis syndrome
• Reduced or absent activity: Suggests xanthinuria or molybdenum cofactor deficiency

Clinical Significance and Therapeutic Relevance

Xanthine oxidase diagnostics is relevant not only for rare inherited metabolic disorders but also for common conditions such as gout and hyperuricemia. The targeted inhibition of xanthine oxidase by medications such as allopurinol or febuxostat is an established treatment strategy for lowering uric acid levels. Diagnostics enable clinicians to identify patients who may benefit from such therapy and to tailor treatment individually. Moreover, xanthine oxidase plays a role in inflammatory processes and oxidative stress, making it a research target in cardiovascular disease.

References

1. Reiter, S., Simmonds, H. A., Zollner, N. et al. - Demonstration of a combined deficiency of xanthine oxidase and aldehyde oxidase in xanthinuria type II. In: Clinica Chimica Acta, 187(3):221-234, 1990.
2. Ichida, K., Amaya, Y., Okamoto, K., Nishino, T. - Mutations associated with functional disorder of xanthine dehydrogenase and hereditary xanthinuria in humans. In: International Journal of Molecular Sciences, 13(11):15475-15495, 2012.
3. Borghi, C., Domienik-Karlowicz, J., Tykarski, A. et al. - Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk. In: Cardiology Journal, 28(1):1-21, 2021.